Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Leuk Lymphoma ; 43(11): 2139-43, 2002 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-12533039

RESUMO

High-dose methotrexate (HDMTX) is a component of many cancer treatment regimens. Despite careful management, delayed renal clearance, followed by extremely high serum levels with potentially life-threatening toxicity can occur. In the present study, we report our results of carboxypeptidase-G2 (CPDG2) rescue in 8 patients with delayed methotrexate elimination and renal impairment after HDMTX therapy for lymphoma or osteosarcoma. A dose of 50 U/kg CPDG2 was administered. MTX plasma levels decreased rapidly and recovery of renal function was observed in all patients. No patient developed severe WHO grade 4 MTX toxicity. CPDG2 provides an alternative route of MTX elimination by converting it to inactive and non-toxic metabolites. CPDG2 rescue was well tolerated, safe and very effective in preventing severe or life-threatening MTX toxicity.


Assuntos
Metotrexato/toxicidade , Neoplasias/tratamento farmacológico , gama-Glutamil Hidrolase/administração & dosagem , Adulto , Antídotos/administração & dosagem , Feminino , Humanos , Nefropatias/induzido quimicamente , Linfoma/complicações , Linfoma/tratamento farmacológico , Masculino , Metotrexato/sangue , Metotrexato/farmacocinética , Pessoa de Meia-Idade , Neoplasias/complicações , Osteossarcoma/complicações , Osteossarcoma/tratamento farmacológico , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...